keyword
MENU ▼
Read by QxMD icon Read
search

Macrolide AND pneumonia

keyword
https://www.readbyqxmd.com/read/27914135/is-%C3%AE-lactam-plus-macrolide-more-effective-than-%C3%AE-lactam-plus-fluoroquinolone-among-patients-with-severe-community-acquired-pneumonia-a-systemic-review-and-meta-analysis
#1
Jong Hoo Lee, Hyun Jung Kim, Yee Hyung Kim
Adding either macrolide or fluoroquinolone (FQ) to β-lactam has been recommended for patients with severe community-acquired pneumonia (CAP). However, due to the limited evidence available, there is a question as to the superiority of the two combination therapies. The MEDLINE, EMBASE, Cochrane Central Register, Scopus, and Web of Science databases were searched for systematic review and meta-analysis. A total of eight trials were analyzed. The total number of patients in the β-lactam plus macrolide (BL-M) and β-lactam plus fluoroquinolone (BL-F) groups was 2,273 and 1,600, respectively...
January 2017: Journal of Korean Medical Science
https://www.readbyqxmd.com/read/27912925/cardiac-arrest-in-pediatric-patients-receiving-azithromycin
#2
Santiago O Valdés, Jeffrey J Kim, Mary C Niu, Caridad M de la Uz, Christina Y Miyake, Brady S Moffett
OBJECTIVE: To compare outcomes of pediatric patients treated with azithromycin compared with penicillin or cephalosporin. We hypothesized that azithromycin use would not be associated with increased cardiac mortality in the pediatric population. STUDY DESIGN: Retrospective cohort study from the Pediatric Health Information System database between 2008 and 2012. Patients <19 years of age with a principal diagnosis of community-acquired pneumonia who received an antibiotic were included...
November 29, 2016: Journal of Pediatrics
https://www.readbyqxmd.com/read/27909995/solithromycin-a-novel-fluoroketolide-for-the-treatment-of-community-acquired-bacterial-pneumonia
#3
REVIEW
George G Zhanel, Erika Hartel, Heather Adam, Sheryl Zelenitsky, Michael A Zhanel, Alyssa Golden, Frank Schweizer, Bala Gorityala, Philippe R S Lagacé-Wiens, Andrew J Walkty, Alfred S Gin, Daryl J Hoban, Joseph P Lynch, James A Karlowsky
Solithromycin is a novel fluoroketolide developed in both oral and intravenous formulations to address increasing macrolide resistance in pathogens causing community-acquired bacterial pneumonia (CABP). When compared with its macrolide and ketolide predecessors, solithromycin has several structural modifications which increase its ribosomal binding and reduce its propensity to known macrolide resistance mechanisms. Solithromycin, like telithromycin, affects 50S ribosomal subunit formation and function, as well as causing frame-shift errors during translation...
December 1, 2016: Drugs
https://www.readbyqxmd.com/read/27906087/legionella-pneumonia-in-the-niagara-region-ontario-canada-a-case-series
#4
Stephanie Cargnelli, Jeff Powis, Jennifer L Y Tsang
BACKGROUND: Legionella pneumophila, a major cause of Legionnaires' disease, accounts for 2-15 % of all community-acquired pneumonia requiring hospitalization and up to 30 % of community-acquired pneumonia requiring intensive care unit admission. Early initiation of appropriate antimicrobial therapy is a crucial step in the prevention of morbidity and mortality. However, recognition of Legionnaires' disease continues to be challenging because of its nonspecific clinical features. We sought to describe hospitalized community-acquired Legionnaires' disease to increase awareness of this important and potentially lethal disease...
December 1, 2016: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/27855075/in-vitro-activity-of-lefamulin-and-other-antimicrobial-agents-against-macrolide-susceptible-and-macrolide-resistant-mycoplasma-pneumoniae-from-the-united-states-europe-and-china
#5
Ken B Waites, Donna M Crabb, Lynn B Duffy, Jorgen S Jensen, Yang Liu, Susanne Paukner
Lefamulin, an investigational pleuromutilin, was tested against a collection of 18 macrolide-susceptible and 42 macrolide-resistant Mycoplasma pneumoniae strains in comparison to azithromycin, erythromycin, tetracycline, doxycycline, and moxifloxacin. Lefamulin was highly active against all strains tested, with all MICs ≤ 0.008 μg/ml. The lefamulin MIC90 (0.002 μg/ml) for macrolide-resistant strains was the lowest among all drugs tested. Minimum bactericidal concentrations were within 2 dilutions of the MIC values, indicating a bactericidal effect...
November 14, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27805513/microbiologic-monitoring-of-kidney-transplant-recipients-before-transplant
#6
Nelya Bissenova, Aigerim Yergaliyeva
OBJECTIVES: Drug immunosuppression, traditionally used to minimize autoimmune developments after liver, kidney, heart, and lung transplant, and which requires high doses of corticosteroids, creates favorable conditions for the development of various infectious processes and the existence of pathogens, which can be activated after transplant. This study aimed to investigate the bacterial pathogens in patients before living-donor kidney transplant. MATERIALS AND METHODS: We prospectively investigated 117 clinical samples of 33 patients who were seen during 2015 at the National Scientific Research Center (Astana, Kazakhstan) before living-donor kidney transplant...
November 2016: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/27789313/development-of-an-endpoint-genotyping-assay-to-detect-the-mycoplasma-pneumoniae-23s-rrna-gene-and-distinguish-the-existence-of-macrolide-resistance-associated-mutations-at-position-2063
#7
Yu Suzuki, Junji Seto, Yoshitaka Shimotai, Tatsuya Ikeda, Kazue Yahagi, Katsumi Mizuta, Yoko Matsuzaki, Seiji Hongo
The prevalence of macrolide-resistant Mycoplasma pneumoniae harboring a mutation in the 23S rRNA gene is increasing, and rapid detection assays are needed for clinical management. We developed an endpoint genotyping assay to detect the M. pneumoniae 23S rRNA gene and determine the existence of macrolide resistance-associated mutations at position 2063 (A2063G, A2063T and A2063C mutations). This A2063B genotyping assay detected more than 50 copies/reaction of the M. pneumoniae gene in every nucleotide mutation at position 2063...
October 24, 2016: Journal of Microbiological Methods
https://www.readbyqxmd.com/read/27753516/solithromycin-for-the-treatment-of-community-acquired-bacterial-pneumonia
#8
Diego Viasus, Oscar Ramos, Leidy Ramos, Antonella F Simonetti, Jordi Carratalà
Community-acquired pneumonia is a major public health problem worldwide. In recent years, there has been an increase in the frequency of resistance to the antimicrobials such as β-lactams or macrolides which have habitually been used against the causative pathogens. Solithromycin, a next-generation macrolide, is the first fluoroketolide with activity against most of the frequently isolated bacteria in community-acquired pneumonia, including typical and atypical bacteria as well as macrolide-resistant Streptococcus pneumoniae...
October 31, 2016: Expert Review of Respiratory Medicine
https://www.readbyqxmd.com/read/27742734/pleuromutilins-potent-drugs-for-resistant-bugs-mode-of-action-and-resistance
#9
Susanne Paukner, Rosemarie Riedl
Pleuromutilins are antibiotics that selectively inhibit bacterial translation and are semisynthetic derivatives of the naturally occurring tricyclic diterpenoid pleuromutilin, which received its name from the pleuromutilin-producing fungus Pleurotus mutilus Tiamulin and valnemulin are two established derivatives in veterinary medicine for oral and intramuscular administration. As these early pleuromutilin drugs were developed at a time when companies focused on major antibacterial classes, such as the β-lactams, and resistance was not regarded as an issue, interest in antibiotic research including pleuromutilins was limited...
October 14, 2016: Cold Spring Harbor Perspectives in Medicine
https://www.readbyqxmd.com/read/27739904/clinical-utility-of-testing-for-legionella-pneumonia-in-central-texas
#10
Christopher Henry, Carl Boethel, Laurel A Copeland, Shekhar Ghamande, Alejandro C Arroliga, Heath D White
RATIONALE: Legionella pneumophila is an uncommon cause of community-acquired pneumonia in south central United States and regular testing may not be cost-effective in areas of low incidence. OBJECTIVES: To evaluate the incidence of Legionella in central Texas and determine the costeffectiveness of Legionella urinary antigen testing. METHODS: We performed a single-center retrospective cohort study of patients admitted with pneumonia between January 2001 and December 2013...
October 14, 2016: Annals of the American Thoracic Society
https://www.readbyqxmd.com/read/27721280/in-vitro-activity-of-ceftaroline-a-novel-antibiotic-against-methicillin-resistant-staphylococcus-aureus
#11
Vaishali Gaikwad, Tejash Gohel, Shrijeet Panickar, Vijay Chincholkar, Santosh Mangalkar
INTRODUCTION: Staphylococcus is one of the most common causes of nosocomial infection, especially pneumonia, surgical site infections, blood stream infections, and continues to be a major cause of community-acquired infections. The emergence of penicillin resistance followed by the development and spread of strains resistant to the semisynthetic penicillins such as methicillin, oxacillin and nafcillin, macrolides, tetracycline, and aminoglycosides has made the treatment of staphylococcal infection a global challenge...
October 2016: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/27709102/macrolide-resistance-in-streptococcus-pneumoniae
#12
Max R Schroeder, David S Stephens
Streptococcus pneumoniae is a common commensal and an opportunistic pathogen. Suspected pneumococcal upper respiratory infections and pneumonia are often treated with macrolide antibiotics. Macrolides are bacteriostatic antibiotics and inhibit protein synthesis by binding to the 50S ribosomal subunit. The widespread use of macrolides is associated with increased macrolide resistance in S. pneumoniae, and the treatment of pneumococcal infections with macrolides may be associated with clinical failures. In S...
2016: Frontiers in Cellular and Infection Microbiology
https://www.readbyqxmd.com/read/27697049/macrolide-hybrid-compounds-drug-discovery-opportunities-in-anti-infective-and-anti-inflammatory-area
#13
Hana Čipčić Paljetak, Linda Tomašković, Mario Matijašić, Mirjana Bukvić, Andrea Fajdetić, Donatella Verbanac, Mihaela Perića
5-LOX - 5-lipoxygenase; ACT - artemisinin-based combination therapies; ADME - absorption, distribution, metabolism and excretion; BAL - broncho alveolar lavage; CABP - community acquired bacterial pneumonia; cAMP - cyclic adenosine monophosphate; CAP - community-acquired pneumonia; CF - cystic fibrosis, BOS bronchiolitis obliterans syndrome; cGMP - cyclic guanosine monophosphate; COPD - chronic obstructive pulmonary disease; COX - cyclooxygenase; DPB - diffuse panbronchiolitis; HDACs - histone deacetylases; IBD - inflammatory bowel disease; IL-1p - interleukin 1p; IL-6 - interleukin 6; MIC - minimal inhibitory concentrations; MLSB - macrolide, lincosamide, streptogramin B; NSAIDs - non-steroidal anti-inflammatory drugs; OVA - ovalbumin; PDE4 - phosphodiesterase 4; PMA - phorbol 12-myristate 13-acetate; RA - rheumatoid arthritis; RTI - respiratory tract infections; SAHA - suberoylanilide hydroxamic acid; SAR - structure-activity-relationship; Th1 - type 1 helper T-cell; TNBS - trinitrobenzene sulfonic acid; TNF-α - tumour necrosis factor α; UN - United Nations, WHO - World Health Organisation...
September 27, 2016: Current Topics in Medicinal Chemistry
https://www.readbyqxmd.com/read/27671057/in-vitro-activities-of-omadacycline-ptk-0796-and-other-antimicrobial-agents-against-human-mycoplasmas-and-ureaplasmas
#14
Ken B Waites, Donna M Crabb, Yang Liu, Lynn B Duffy
In vitro activities of omadacycline, a new aminomethylcycline, were determined for Mycoplasma and Ureaplasma spp. in comparison to azithromycin, clindamycin, moxifloxacin, tetracycline, and doxycycline. All omadacycline MICs were < 2 μg/ml. MIC90s were 0.063 μg/ml for Mycoplasma hominis, 0.25 μg/ml for Mycoplasma pneumoniae, and 2 μg/ml for Ureaplasma spp. Omadacycline had the lowest MIC90 among all drugs tested against M. hominis Omadacycline activity was not affected by macrolide, tetracycline, or fluoroquinolone resistance...
September 26, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27661056/two-case-reports-whole-genome-sequencing-of-two-clinical-macrolide-resistant-mycoplasma-pneumoniae-isolates-with-different-responses-to-azithromycin
#15
Shaoli Li, Hongmei Sun, Fei Liu, Yanling Feng, Hanqing Zhao, Guanhua Xue, Chao Yan
BACKGROUND: Cases of macrolide-resistant Mycoplasma pneumoniae have increased rapidly since 2000, especially in Asia. Patients infected with macrolide-resistant M pneumoniae usually present with severe M pneumoniae pneumonia. The aim of this study was to identify indicators for whether children at an early stage of M pneumoniae infection develop mild or severe pneumonia. CASE SUMMARY: Herein, we retrospectively reviewed 2 pediatric cases caused by macrolide-resistant M pneumoniae, but with markedly different severity of pneumonia...
September 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27660779/draft-genome-sequence-of-a-klebsiella-pneumoniae-strain-new-sequence-type-2357-carrying-tn3926
#16
Xing-Bei Weng, Zu-Huang Mi, Chun-Xin Wang, Jian-Ming Zhu
We present the draft genome sequence of a Klebsiella pneumoniae carbapenemase-producing sequence type 2357 (ST2357) strain, NB60, which contains drug-resistant genes encoding resistance to beta-lactams, fluoroquinolones, aminoglycosides, trimethoprim-sulfamethoxazole, colistin, macrolides, and tetracycline. Strain NB60 was isolated from human blood, making it an important tool for studying K. pneumoniae pathogenesis.
2016: Genome Announcements
https://www.readbyqxmd.com/read/27621174/a-new-mosaic-integrative-and-conjugative-element-from-streptococcus-agalactiae-carrying-resistance-genes-for-chloramphenicol-catq-and-macrolides-mef-i-and-erm-tr
#17
Eleonora Morici, Serena Simoni, Andrea Brenciani, Eleonora Giovanetti, Pietro E Varaldo, Marina Mingoia
OBJECTIVES: To investigate the genetic basis of catQ-mediated chloramphenicol resistance in Streptococcus agalactiae. METHODS: Two clinical strains of catQ-positive chloramphenicol-resistant S. agalactiae (Sag236 and Sag403) were recently isolated, typed (MLST, PFGE pulsotypes, capsular types) and their antibiotic resistances investigated by phenotypic and genotypic approaches. Several molecular methods (PCR mapping, restriction assays, Southern blotting, sequencing and sequence analysis, conjugal transfer assays) were used to determine the genetic context of catQ and characterize a genetic element detected in the isolates...
September 12, 2016: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/27620481/in-vitro-activity-of-solithromycin-against-bordetella-pertussis-an-emerging-respiratory-pathogen
#18
Dwight J Hardy, David Vicino, Prabhavathi Fernandes
There has been an increase in the number of pertussis cases reported since the introduction of the acellular pertussis vaccine. While children that present with pertussis have a characteristic whooping cough, adults can simply have a persistent, non-specific cough and remain undiagnosed. Macrolide antibiotics, such as azithromycin, are the currently recommended treatment for pertussis. Solithromycin is a new macrolide and the first fluoroketolide, with broad activity against a wide spectrum of bacterial pathogens and has completed clinical development for community-acquired bacterial pneumonia (CABP)...
September 12, 2016: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/27595539/the-solithromycin-journey-it-is-all-in-the-chemistry
#19
Prabhavathi Fernandes, Evan Martens, Daniel Bertrand, David Pereira
The macrolide class of antibiotics, including the early generation macrolides erythromycin, clarithromycin and azithromycin, have been used broadly for treatment of respiratory tract infections. An increase of treatment failures of early generation macrolides is due to the upturn in bacterial macrolide resistance to 48% in the US and over 80% in Asian countries and has led to the use of alternate therapies, such as fluoroquinolones. The safety of the fluoroquinolones is now in question and alternate antibiotics for the outpatient treatment of community acquired bacterial pneumonia are needed...
August 22, 2016: Bioorganic & Medicinal Chemistry
https://www.readbyqxmd.com/read/27567896/severe-community-acquired-pneumonia-timely-management-measures-in-the-first-24-hours
#20
REVIEW
Jason Phua, Nathan C Dean, Qi Guo, Win Sen Kuan, Hui Fang Lim, Tow Keang Lim
Mortality rates for severe community-acquired pneumonia (CAP) range from 17 to 48 % in published studies.In this review, we searched PubMed for relevant papers published between 1981 and June 2016 and relevant files. We explored how early and aggressive management measures, implemented within 24 hours of recognition of severe CAP and carried out both in the emergency department and in the ICU, decrease mortality in severe CAP.These measures begin with the use of severity assessment tools and the application of care bundles via clinical decision support tools...
August 28, 2016: Critical Care: the Official Journal of the Critical Care Forum
keyword
keyword
37631
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"